METHOD FOR DIAGNOSING ALLERGIC BRONCHIAL ASTHMA Russian patent published in 2022 - IPC G01N33/49 G01N33/577 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to molecular immunology and allergology, and can be used to diagnose allergic bronchial asthma. Monoclonal antibodies to TNFRI, TNFR2, CD19, CD5, CD4, CD8, CD45RA are added to blood samples. Peripheral blood mononuclear cells are analyzed by flow cytometry. CD19+CD5+ B-lymphocytes, naive cytotoxic cells CD8+CD45RA+, T-helper cells CD4+ are isolated by gating. the expression indicators of TNFR1 and TNFR2 receptors are determined by counting the number of receptors on the cells of the studied subpopulations. The percentage of cells carrying TNFRI and TNFR2 receptors in each isolated subpopulation is determined. Based on a parametric logistic regression model, the probability of having allergic bronchial asthma is calculated using the formula: , where e=2.7182818 - mathematical constant - base of the natural logarithm, α₀ = 12.455816360508 - coefficient, α₁ = -0.427698308974449 - coefficient, α₂ = -0.006454484262661 - coefficient, α₃ = -0.005092094923 - coefficient, x₁ = percentage of cells bearing both TNFR1 and TNFR2 receptors among CD19+CD5+ B lymphocytes, x₂ = mean number of type 1 receptors on TNFR1-positive CD8+CD45RA+ cytotoxic naive T lymphocytes, x₃ = mean number of receptors 1- type on TNFR1-positive CD4+ T-helper cells. If P is greater than or equal to 0.5, then the presence of allergic bronchial asthma is diagnosed.

EFFECT: method enables the diagnosis of allergic bronchial asthma by assessing the average number of receptors and the percentage of cells expressing type 1 and type 2 receptors for TNF-α on subpopulations of mononuclear cells in patients with suspected bronchial asthma.

1 cl, 3 dwg, 4 ex